Valuation: MacroGenics, Inc.

Market Cap 262M 229M 211M 195M 367M 25.22B 375M 2.52B 993M 12.35B 983M 962M 42.52B P/E 2026 *
-6.14x
P/E 2027 * -2.7x
Enterprise Value 262M 229M 211M 195M 367M 25.22B 375M 2.52B 993M 12.35B 983M 962M 42.52B EV / Sales 2026 *
1.59x
EV / Sales 2027 * 2.78x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+5.95%
1 week+0.46%
Current month-5.84%
1 month+9.85%
3 months+25.73%
6 months+148.58%
Current year+170.19%
1 week 4
Extreme 4.005
4.54
1 month 3.96
Extreme 3.965
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 71 01/07/2020
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Chairman

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+5.95%+0.46%+182.47%-13.86% 262M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.72%-6.12%+4.20%+424.35% 23.29B
-0.03%+0.05%-17.56%-14.62% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
-0.23%-1.56%+23.96%+189.84% 14B
Average -1.95%-2.12%+57.78%+165.52% 24.07B
Weighted average by Cap. -2.94%-2.21%+43.42%+144.86%

Financials

2026 *2027 *
Net sales 164M 144M 133M 122M 230M 15.83B 235M 1.58B 623M 7.75B 617M 604M 26.69B 94.26M 82.37M 76.01M 70.06M 132M 9.08B 135M 909M 357M 4.45B 354M 346M 15.3B
Net income -18.31M -16M -14.76M -13.61M -25.65M -1.76B -26.22M -176M -69.4M -863M -68.75M -67.24M -2.97B -127M -111M -102M -94.43M -178M -12.23B -182M -1.22B -482M -5.99B -477M -467M -20.63B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
18/07/26 US$4.350 +5.58% 293,757
16/07/26 US$4.120 -4.63% 898,793
15/07/26 US$4.320 +0.70% 592,219
14/07/26 US$4.290 -4.67% 1,279,751
13/07/26 US$4.500 +3.93% 1,124,151
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.120USD
Average target price
6.750USD
Spread / Average Target
+63.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock